2. Signaling Pathways
  3. GPCR/G Protein
  4. P2Y Receptor
  5. P2Y14 Receptor Isoform

P2Y14 Receptor

 

P2Y14 Receptor Related Products (17):

Cat. No. Product Name Effect Purity
  • HY-N7032
    Uridine 5′-diphosphoglucose disodium
    		Agonist 99.98%
    Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
  • HY-114364
    UDP-Galactose disodium
    		Agonist 99.42%
    UDP-Galactose disodium is a natural agonist of the P2Y14 receptor with an EC50 of 0.67 μM for the hP2Y14 receptor. UDP-Galactose disodium is a substrate for the transferase beta-1, 4 galactosyltransferase V (B4GALT5). In addition, UDP-Galactose disodium is required for the biosynthesis of several abundant glycoconjugates that form the surface glycocalyx of Leishmania major.
  • HY-110322A
    PPTN
    		Antagonist 99.63%
    PPTN, a chemical probe, is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity.
  • HY-113044R
    Uridine 5′-diphosphoglucose (Standard)
    		Agonist
    Uridine 5′-diphosphoglucose (Standard) (UDP-D-Glucose (Standard)) is the analytical standard of Uridine 5′-diphosphoglucose (HY-113044). This product is intended for research and analytical applications. Uridine 5’-diphosphoglucose (UDP-glucose), secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
  • HY-162661
    P2Y14R antagonist 2
    		Antagonist 99.56%
    P2Y14R antagonist 2 (compound 39) is a potent, selective and orally active P2Y14R antagonist with an IC50 value of 0.40 nM. P2Y14R antagonist 2 shows anti-inflammatory activity. P2Y14R antagonist 2 has the potential for the research of colitis.
  • HY-178006
    MRS4917
    		Antagonist
    MRS4917 is an orally active, potent selective P2Y14 receptor (hP2Y14R) antagonist (IC50 = 2.88 nM, Ki = 1.67 nM) that shows >18,000 fold selectivity against P2Y6R (IC50 = 54 μM). MRS4917 demonstrates oral efficacy in reversing established mechanoallodynia in the chronic constriction injury (CCI) mouse model, while having no effect on thermoregulation. MRS4917 can be used for neurological diseases research.
  • HY-173407
    P2Y14R antagonist 4
    		Antagonist
    P2Y14R antagonist 4 (Compound 25l) is an orally active P2Y14R antagonist (IC50: 5.6 nM) with superior binding affinity to P2Y14R over PPTN. P2Y14R antagonist 4 has anti-inflammatory activity and reduces LPS (HY-D1056)-induced proinflammatory cytokines (IL-1β, IL-6, and TNF-α) release.
  • HY-137607A
    UDP trisodium
    		Agonist
    UDP trisodium (Compound 3), a nucleotide, is a P2Y14 receptor agonist with an EC50 of 160  nM for P2Y14 receptor over the P2Y6 receptor. UDP trisodium can be used for pain, diabetes, cystic fibrosis and other pulmonary diseases research.
  • HY-161727
    P2Y14R antagonist 1
    		Antagonist 98.58%
    P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis.
  • HY-113044
    Uridine 5′-diphosphoglucose
    		Agonist
    Uridine 5’-diphosphoglucose (UDP-glucose), secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
  • HY-150524
    UDP-Galactose
    		Agonist
    UDP-Galactose is a monosaccharide involved in nucleotide sugar metabolism. UDP-Galactose and its derivatives act as a natural agonist for Gi protein-conjugated P2Y14 receptors in the immune system (IC50=0.67 μM, hP2Y14).
  • HY-167855
    MRS4833
    		Antagonist
    MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model.
  • HY-161343
    HDL-16
    		Antagonist 99.19%
    HDL-16 is a potent P2Y14R antagonist with an IC50 of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function.
  • HY-172226
    P2Y14R antagonist 3
    		Antagonist
    P2Y14R antagonist 3 (Compound A) is a potent and orally active P2Y14R antagonist with an IC50 value of 23.60 nM and a Kd value of 7.26 μM. P2Y14R antagonist 3 can reduce the degree of lung injury in the Lipopolysaccharides (LPS) (HY-D1056)-induced acute lung injury mice. P2Y14R antagonist 3 can be used for inflammatory diseases.
  • HY-176739
    P2Y14R antagonist 5
    		Antagonist
    P2Y14R antagonist 5 (Compound A) is a novel P2Y14R antagonist based on a benzisoxazole skeleton (IC50: 23.60 nM, KD: 7.26 μM). P2Y14R antagonist 5 reduces the levels of proinflammatory cytokines (IL-1β, IL-6, TNF-α) and myeloperoxidase (MPO). P2Y14R antagonist 5 has anti-inflammatory activity in a mouse model of LPS-induced acute lung injury.
  • HY-148596
    UDP-GlcNAc
    		Agonist
    UDP-GlcNAc is an essential building block and precursor of bacterial peptidoglycan.
  • HY-110369
    MRS2905 trisodium
    		Agonist
    MRS2905 (α,β-Methylene-2-thio-UDP) trisodium is a selective P2Y14R agonist with an EC50 of 0.92 nM. MRS2905 trisodium is inactive at the UDP-activated P2Y6 receptor, and at other P2Y receptors.